REFERENCES

  1. Xu Y, Wu Prevalence trend and disparities in rheumatoid arthritis among US adults, 2005-2018. J Clin Med 2021;10:3289.
  2. Helmick CG, Felson DT, Lawrence RC, et Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
  3. American College of Rheumatology. 2021. Rheumatoid Arthritis. https://rheumatology.org/patients/rheumatoid-arthritis
  4. Cross M, Smith E, Hoy D, et The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73:1316-22.
  5. Hsieh P-H, Wu O, Geue C, et Economic burden of rheumatoid arthritis: a systematic review of literature in the biologic era. Ann Rheum Dis 2020;79:771-77.
  6. Agarwal Core management principles in rheumatoid arthritis to help guide managed care professionals. J Manag Care Pharm 2011;17(9 Suppl B):S03-S08.
  7. National Institute of Arthritis and Musculoskeletal and Skin Rheumatoid arthritis. National Institutes of Health; 2022. https://www.niams.nih.gov/health-topics/rheumatoid-arthritis.
  8. Mayo Clinic. Rheumatoid arthritis: symptoms and causes. https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648; 2022.
  9. Centers for Disease Control and Rheumatoid arthritis (RA). https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html; 2020.
  10. Demoruelle MK, Deane KD, Holers When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol 2014;26:64-71.
  11. England BR, Tiong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken) 2019;71:1540-55.
  12. Barber CEH, Zell J, Yazdany J, et 2019 American College of Rheumatology recommended patient-reported functional status assessment measures in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2019;71:1531-39.
  13. England BR, Barber CEH, Bergman M, et al. Adaptation of American College of Rheumatology rheumatoid arthritis disease activity and functional status measures for telehealth visits. Arthritis Care Res (Hoboken) 2021;73:1809-14.
  14. Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol 2018;70:1544-54.
  15. Kilic G, Ozgocmen Hand bone mass in rheumatoid arthritis: A review of the literature. World J Orthop 2015;6:106-16.
  16. Baker JF. Diagnosis and differential diagnosis of rheumatoid Waltham MA: UptoDate Inc. 2022. https://www.uptodate.com Accessed December 8, 2022.
  17. American College of Rheumatology. Antinuclear antibodies (ANA). 2021. https://rheumatology.org/patients/antinuclear-antibodies-ana.
  18. Nashi RA, Shmerling Antinuclear antibody testing for the diagnosis of systemic lupus erythematosus. Rheum Dis Clin North Am 2022;48:569-78.
  19. Johns Hopkins University Lupus Lupus blood tests. Johns Hopkins University; 2021. https://www.hopkinslupus.org/lupus-tests/lupus-blood-tests
  20. Aletaha D, Neogi T, Silman AJ, et 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaboration initiative. Arthritis Rheum 2010;62:2569-81.
  21. Marks M, Marks Viral arthritis. Clin Med (Lond) 2016;16:129-34.
  22. Farisogullari B, Pinto AS, Machado PM. COVID-19-associated arthritis: an emerging new entity? RMD Open 2022;8:e002026.
  23. Alberta Health Comparing rheumatoid arthritis and osteoarthritis. https://myhealth.alberta.ca/Health/Pages/conditions. aspx?hwid=aa19377; 2022.
  24. National Institute of Arthritis and Musculoskeletal and Skin Dis Psoriatic arthritis. https://www.niams.nih.gov/health-topics/psoriatic-arthritis; 2021.
  25. Centers for Disease Control and Lyme arthritis. https://www.cdc.gov/lyme/treatment/LymeArthritis.html; 2021.
  26. Office on Women’s Health. Lupus diagnosis and treatment. https://www.womenshealth.gov/lupus/lupus-diagnosis-and-treatment: Office of the Assistant Secretary for Health at the US Depart- ment of Health and Human Services; 2021.
  27. National Institute of Diabetes and Digestive and Kidney Ulcerative colitis. National Institutes of Health; 2022. https:// www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis
  28. Arvikar SL, Fisher Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med 2011;4:123-31.
  29. Chen Y, Chen L, Xing C, et The risk of rheumatoid arthritis among patients with inflammatory bowel disease: a systematic re- view and meta-analysis. BMC Gastroenterol 2020;20:Article number 192.
  30. National Institute of Diabetes and Digestive and Kidney Ulcerative colitis. National Institutes of Health; 2022. https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis
  31. National Institute of Diabetes and Digestive and Kidney Diseas Crohn’s disease. National Institutes of Health; 2022. https://www.niddk.nih.gov/health-information/digestive-diseases/crohns-disease
  32. Hanahan D, Weinberg Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
  33. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid Arthritis Care Res (Hoboken) 2021;73:924-39.
  34. Aletaha D, Smolen Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018;320:1360-72.
  35. Crofford Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013;15 (Suppl 3):S2.
  36. Johns Hopkins Arthritis Center. Rheumatoid arthritis treatment. https://www.hopkinsarthritis.org/arthritis-info/rheumatoid-arthritis/ ra-treatment/#new; 2022.
  37. Vonkeman HE, van de Laar Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 2010;39:294-312.
  38. Malysheva O, Baerwald Low-dose corticosteroids and disease modifying drugs in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:S113-S15.
  39. Volkmann Tapering glucocorticoids in rheumatoid arthritis. Lancet 2020;396:218-19.
  40. Singh JA, Saag KG, Bridges Jr SL, et 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
  41. Smolen JS, Landewé R, Bijlsma J, et EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
  42. Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid Ann Rheum Dis 2017;76:1113-36.
  43. Romão VC, Lima A, Bernardes M, Canhao H, Fonseca JE. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? Immunol Res 2014;60:289-310.
  44. US Food and Drug Plaquenil® hydroxychloroquine sulfate tablets, USP. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf
  45. US Food and Drug Administration. Arava® tablets (leflunomide) prescribing information. 2022. https://www.accessdata.fda.gov/drug-satfda_docs/label/2011/020905s022lbl.pdf
  46. US Food and Drug Methotrexate Injection, USP. https://www.accessdata.fda.gov/drugsatfda_docs/la- bel/2018/011719s126lbl.pdf
  47. US Food and Drug Administration. Azulfidine® sulfasalazine tablets, USP. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf
  48. US Food and Drug Humira® (adalimumab) highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf
  49. US Food and Drug Cimzia® (certolizumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125160s189lbl.pdf
  50. US Food and Drug Administration. Enbrel®(etanercept) highlights of prescribing information. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2021/103795s5582lbl.pdf
  51. US Food and Drug Simponi ARIA® (golimum- ab) highlights of prescribing information. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-pi.pdf; 2009.
  52. US Food and Drug Administration. Renflexis® (infliximab-abda) highlights of prescribing information. https://www.accessdata.fda. gov/drugsatfda_docs/label/2017/761054orig1s000lbl.pdf.
  53. US Food and Drug Kevzara (sarilumab) highlights of prescribing information. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2018/761037s001lbl.pdf
  54. US Food and Drug Administration. Actemra (tocilizumab) highlights of prescribing information. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2017/125276s114lbl.pdf.
  55. US Food and Drug Administration. Ruxience (rituximab-pvvr) highlights of prescribing https://www.accessdata.fda. gov/drugsatfda_docs/label/2021/761103s005lbl.pdf
  56. US Food and Drug Orencia (abatacept) highlights of prescribing information. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2013/125118s171lbl.pdf
  57. US Food and Drug Kineret (anakinra) highlights of prescribing information. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2020/103950s5189lbl.pdf
  58. US Food and Drug Olumiant (baricitinib) highlights of prescribing information. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2022/207924s006lbl.pdf
  59. US Food and Drug Xeljanz (tofacitinib) highlights of prescribing information. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2018/203214s018lbl.pdf
  60. US Food and Drug Rinvoq (upadacitinib) highlights of prescribing information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf
  61. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal Arthritis Rheumatol 2020;72:529-56.
  62. Dooling KL, Guo A, Patel M, et Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep 2018;67:103-08.
  63. Solovic I, Sester M, Gomez-Reino JJ, et The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
  64. Cooney JK, Law R-J, Matschke V, et Benefits of exercise in rheumatoid arthritis. J Aging Res 2011;Article No 681640.
  65. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position Diabetes Care 2010;33:e147-e67.
  66. Gwinnutt JM, Wieczorek M, Cavalli G, et Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open 2022;8:e002168.
  67. Gwinnutt JM, Wieczorek M, Rodríguez-Carrio J, et al. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMD Open 2022;8:e002167.
  68. McManus, KD. 2023. A practical guide to the Mediterranean Harvard Health. https://www.health.harvard.edu/blog/a-practical-guide-to-the-mediterranean-diet-2019032116194
  69. Brismar K, Hafström I, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open 2017;3:e000458.
  70. McBurney CA, Vina Racial and ethnic disparities in rheumatoid arthritis. Curr Rheum Rep 2012;14:463-71.
  71. Birnbaum H, Pike C, Kaufman R, et Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77-90.
  72. Solomon DH, Ayanian JZ, Yelin E, et Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res (Hoboken) 2012;64:184-89.
  73. Navarro-Millán I, Rajan M, Lui GE, et al. Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. Semin Arthritis Rheum 2020;50:988-95.
  74. Schmajuk G, Trivedi AN, Solomon DH, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011;305:480-86.
  75. Yip K, Navarro-Millán Racial, ethnic, and healthcare disparities in rheumatoid arthritis. Curr Opin Rheumatol 2021;33:117-21.
  76. Riad M, Dunham DP, Chua JR, et al. Health disparities among Hispanics with rheumatoid arthritis: delay in presentation to rheumatologists contributes to later diagnosis and J Clin Rheumatol 2020;26:279-84.
  77. FitzGerald C, Hurst Implicit bias in healthcare professionals: a systematic review. BMC Med Ethics 2017;18:19.
  78. Joplin S, van der Zwan R, Joshua F, Wong Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int 2015;2015:150568.
  79. Hu D, Juarez DT, Yeboah M, Castillo Interventions to increase medication adherence in African-American and Lati- no populations: a literature review. Hawaii J Med Public Health 2014;73:11-18.
  80. Barton JL, Koenig CJ, Evans-Young G, et The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter. BMC Med Inform Decis Mak 2014;14:104.
  81. United States Census Bureau. United States census QuickFacts. https://www.census.gov/quickfacts/fact/table/US/POP010210; 2022.
  82. Juckett Cross-cultural medicine. Am Fam Physician 2005;72:2267-74.
  83. Juckett Caring for Latino patients. Am Fam Physician 2013;87:48-54.